Aldeyra therapeutics, inc. (ALDX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating expenses:
Research and development

6,633

9,614

16,223

10,664

7,848

8,549

7,880

6,792

6,600

5,545

3,539

3,848

3,369

3,449

3,379

2,834

3,511

3,112

2,076

1,249

1,136

1,403

1,195

663

444

400

666

325

150

Acquired in-process research and development

-

67

-47

-49

6,597

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

3,004

3,213

2,839

3,116

2,985

2,545

3,065

2,373

1,891

1,501

1,475

1,481

1,726

1,205

1,396

1,462

1,455

1,226

1,261

954

972

1,007

772

982

800

832

500

660

141

Loss from operations

-9,638

-12,895

-19,016

-13,731

-17,431

-11,094

-10,946

-9,166

-8,491

-7,046

-5,015

-5,330

-5,095

-4,655

-4,776

-4,296

-4,967

-4,338

-3,337

-2,203

-2,108

-2,411

-1,968

-1,646

-1,244

-1,232

-1,166

-985

-291

Other income (expense):
Change in fair value of preferred stock warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-567

-1,759

-93

-940

36

277

Change in fair value of convertible preferred stock rights and rights option liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,546

9,551

-531

-3,390

Interest income

210

278

330

432

499

525

163

141

122

124

56

48

31

27

27

21

24

-

-

-

-

0

0

0

0

0

0

0

0

Other expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-

Interest expense

439

544

29

28

1

63

28

26

28

32

27

26

26

26

26

27

25

27

28

28

28

33

41

56

113

114

14

15

15

Total other income (expense), net

-229

-265

301

404

497

461

134

115

94

92

29

21

4

1

1

-5

-0

-16

-28

-28

-28

-33

-41

511

1,646

10,527

10,475

-583

-3,683

Loss before income taxes

-9,868

-13,160

-18,715

-13,327

-16,934

-10,633

-10,812

-9,050

-8,397

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit

-

0

0

0

-1,309

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-9,868

-13,160

-18,715

-13,327

-15,624

-10,633

-10,812

-9,050

-8,397

-6,954

-4,986

-5,308

-5,091

-4,654

-4,775

-4,302

-4,967

-4,355

-3,365

-2,232

-2,136

-2,444

-2,009

-1,135

401

9,295

9,308

-1,568

-3,974

Net loss per share - basic and diluted

-0.34

-0.48

-0.69

-0.49

-0.58

-0.38

-0.52

-0.46

-0.43

-0.36

-0.32

-0.35

-0.37

-0.35

-0.38

-0.41

-0.51

-

-0.35

-0.27

-

-

-

-

-

-

-

-

-

Weighted average common shares outstanding - basic and diluted

29,210

27,296

27,111

26,985

27,053

26,644

20,969

19,761

19,366

19,172

15,581

15,136

13,797

12,599

12,474

10,622

9,712

-

9,712

8,397

-

-

-

-

-

-

-

-

-

Accretion of preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

141

191

-

189

-

-

Deemed dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,053

-

-

-

-

-

Allocation of undistributed earnings to preferred stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

223

-

8,241

-

-

Accretion of preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

150

123

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,221

-2,009

-5,330

-13

6,049

877

-1,718

-4,098

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.32

-0.68

-0.36

-1.43

-0.04

19.23

2.76

-5.47

-13.03

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.32

2.87

-0.36

-1.56

-4.04

10.70

-9.81

-5.47

-13.03

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,667

5,642

5,565

3,737

327

327

317

314

314

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,667

5,628

5,565

3,769

438

1,813

979

314

314